Scinovex
review Open AccessTop 1% cited

p21 in Cancer Research

Cancers · 2019 · Vol. 11(8) · pp. 1178–1178
Bahar ShamlooSinem Usluer

Abstract

p21 functions as a cell cycle inhibitor and anti-proliferative effector in normal cells, and is dysregulated in some cancers. Earlier observations on p21 knockout models emphasized the role of this protein in cell cycle arrest under the p53 transcription factor activity. Although tumor-suppressor function of p21 is the most studied aspect of this protein in cancer, the role of p21 in phenotypic plasticity and its oncogenic/anti-apoptotic function, depending on p21 subcellular localization and p53 status, have been under scrutiny recently. Basic science and translational studies use precision gene editing to manipulate p21 itself, and proteins that interact with it; these studies have led to regulatory/functional/drug sensitivity discoveries as well as therapeutic approaches in cancer field. In this review, we will focus on targeting p21 in cancer research and its potential in providing novel therapies.

Cancer-related Molecular PathwaysRNA modifications and cancerCancer-related gene regulationEffectorTranscription factorCancer researchCancer cellCancerSuppressorCell cycleBiologyFunction (biology)Phenotype
Citations
338
FWCI
15.14
field-weighted impact
References
176
Percentile
99%
vs. same field & year
Citations per year
References
Genome engineering using the CRISPR-Cas9 system
Nature Protocols · 2013 · 11,552 citations
RNA-triggered gene silencing
Trends in Genetics · 1999 · 619 citations
p21 in cancer: intricate networks and multiple activities
Nature reviews. Cancer · 2009 · 2,716 citations
The emerging role of lncRNAs in cancer
Nature Medicine · 2015 · 2,859 citations
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.